Table 6.
Hras and Ctnnb1 mutations in hepatocellular carcinomas in mice.
| DE-71 | Mutation frequency |
Hras Cdn61 (CAA) |
Ctnnb1 | |||
|---|---|---|---|---|---|---|
| Hras (%) | Ctnnb1 (%) | AAA | CGA | CTA | Cdn 15-46 | |
| Control – Non-tumor liver | 0/8 (0%) | 0/8 (0%) | 0 | 0 | 0 | 0 |
| Control – Spontaneous hepatocellular tumors | 2/17(12%) | 0/17 (05)## | 2 | 0 | 0 | 0 |
| 3 mg/kg | 2/14 (14%) | 3/14 (21%) | 1 | 1 | 0 | 3 |
| 30 mg/kg | 3/19 (16%) | 1/19 (5%) | 2 | 0 | 1 | 1 |
| 100 mg/kg | 1/29 (3%) | 9/29 (31%)** | 1 | 0 | 0 | 9 |
| All DE-71 treated groups (Combined) |
6/62 (105) | 13/62 (21%)* | 4 | 1 | 1 | 13 |
Male and female mice were dosed with 0, 3, 30, or 100 mg/kg PBDE mixture by oral gavage for 2 years. Silent mutations are not included. Non-tumor Liver – 0 mg/kg (3 males +5 females); Liver Tumors- 0 mg/kg (14 males +3 females); 3 mg/kg (12 males +2 females); 30 mg/kg (13 males +6 females); 100 mg/kg (15 males +14 females).
Silent mutations not included.
* p < 0.05, **p < 0.01 by Fisher’s exact test to compare each dose group to the controls ## p < 0.01 for trend by the Cochran–Armitage trend test.